Marinus Pharmaceuticals (NASDAQ:MRNS) was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Thursday.
A number of other research analysts have also recently commented on the company. LADENBURG THALM/SH SH assumed coverage on Marinus Pharmaceuticals in a research note on Wednesday, June 6th. They issued a “buy” rating and a $20.00 target price for the company. ValuEngine upgraded Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. Robert W. Baird assumed coverage on Marinus Pharmaceuticals in a research note on Wednesday, May 23rd. They issued an “outperform” rating and a $15.00 target price for the company. Finally, Mizuho restated a “buy” rating and issued a $13.00 target price on shares of Marinus Pharmaceuticals in a research note on Thursday, April 19th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $18.33.
Marinus Pharmaceuticals opened at $7.07 on Thursday, according to MarketBeat. The company has a market capitalization of $286.08 million, a price-to-earnings ratio of -8.84 and a beta of 2.73. Marinus Pharmaceuticals has a fifty-two week low of $1.27 and a fifty-two week high of $9.87.
Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Wednesday, May 2nd. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.01. sell-side analysts forecast that Marinus Pharmaceuticals will post -0.63 earnings per share for the current year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Barclays PLC purchased a new position in shares of Marinus Pharmaceuticals in the 1st quarter valued at approximately $232,000. JPMorgan Chase & Co. purchased a new position in Marinus Pharmaceuticals during the first quarter valued at $373,000. Artal Group S.A. raised its stake in Marinus Pharmaceuticals by 150.0% during the first quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock valued at $1,910,000 after buying an additional 300,000 shares during the last quarter. 683 Capital Management LLC purchased a new position in Marinus Pharmaceuticals during the fourth quarter valued at $4,488,000. Finally, Millennium Management LLC raised its stake in Marinus Pharmaceuticals by 5.5% during the fourth quarter. Millennium Management LLC now owns 915,620 shares of the biopharmaceutical company’s stock valued at $7,471,000 after buying an additional 47,693 shares during the last quarter. Institutional investors own 56.18% of the company’s stock.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.